NVAX
Novavax Inc.
Company Overview
| Mkt Cap | $1.54B | Price | $8.40 |
| Volume | 3.50M | Change | -0.36% |
| P/E Ratio | -8.2 | Open | $8.33 |
| Revenue | $682.2M | Prev Close | $8.43 |
| Net Income | $-187.5M | 52W Range | $5.01 - $11.55 |
| Div Yield | N/A | Target | $12.63 |
| Overall | 47 | Value | 60 |
| Quality | 47 | Technical | 36 |
No chart data available
Stock Overview
Updated DailyNovavax Inc. (NVAX) is a leading Healthcare company in the Biotechnology industry, currently trading at $8.40 with a market capitalization of $1.54 billion. The stock is trading in the middle of its 52-week range, demonstrating below-average quality metrics with a MarketXLS quality score of 47.
Today's trading session shows NVAX with a volume of 3.50 million shares. The stock opened down 1.19% from yesterday's close of $8.43. Current analyst estimates project earnings of $2.26 per share for this year, with next year targeting $-0.4.
NVAX demonstrates concerning technical signals based on technical analysis. The company trades on the NGS exchange and operates alongside industry peers including SRPT, AGEN, BCRX, EBS, GSK.
Key investment considerations for NVAX include below-average investment characteristics. The company offers a dividend yield of NA% and analyst price targets suggest potential upside of 50.4%. The stock shows fair valuation metrics based on valuation analysis.
Analysis generated on November 3, 2025 at 10:51 AM
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVAX | $8.40 | -0.4% | 3.50M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |